References
- Dewar J . Managing metastatic bone pain. BMJ329(7470), 812–813 (2004).
- Sewell M , NeophytouD , SewellT , HannaS , BriggsT. Management of metastatic bone disease. Geri. Med.33–39 (2012).
- Ross J , SaundersY , EdmondsP , PatelS , BroadleyK , JohnstonS. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ327, 469–72 (2003).
- WHO . WHO’s cancer pain ladder for adults. www.who.int/cancer/palliative/painladder/en/
- Miguel R . Interventional treatment of cancer pain: the fourth step in the world health organization analgesic ladder?Cancer Control7(2), 149–156 (2000).
- Buga S , SarriaJ. The management of pain in metastatic bone disease. Cancer Control19(2), 154–164 (2012).
- Christo P , MazloomdoostD. Interventional pain treatments for cancer pain. Ann. NY Acad. Sci.1138, 299–328 (2008).
- Everdingen M , RijkeJ , KesselsA , SchoutenH , KleefM , PatijnJ. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann. Oncol.18(9), 1437–1449 (2007).
- Roos D , FisherR. Radiotherapy for painful bone metastases: an overview of the overviews. Clin. Oncol.15(6), 342–344 (2003).
- Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet377(9768), 813–22 (2011).
- Jamshidi K , GharehdaghiM , HajialilooS , MirkazemiM , GhaffarzadehganK , IzanlooA. Denosumab in patients with giant cell tumor and its recurrence: a systematic review. Arch. Bone Jt. Surg.6(4), 260–268 (2018).
- Wong R , WiffenP. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst. Rev.2002(2), CD002068 (2002).
- Parker C et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med.369, 213–223 (2013).
- Uemura H . Bone and calcium metabolism associated with malignancy: treatment of radium-223 dichloride for bone metastasis in castration resistant prostate cancer patients. Clin. Calcium28(11), 1485–1493 (2018).
- Portenoy R , CopenhaverD. Cancer pain management: interventional therapies (2017). www.uptodate.com/contents/cancer-pain-management-interventional-therapies
- Sindt J , BroganS. Interventional treatments of cancer pain. Anesthesiol. Clin.34(2), 317–339 (2016).
- Plancarte R , AlvarezJ , ArrietaM. Interventional treatments of cancer pain. Seminars Pain Med.1(1), 34–42 (2003).
- Smith TJ , StaatsPS , DeerTet al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J. Clin. Oncol.20(19), 4040–9 (2002).
- Deer T, Levy RM, Kramer J et al. DRG stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain158(4), 669–681 (2012).
- Jonkman K , DonkT , DahanA. Ketamine for cancer pain: what is the evidence?Curr. Opin. Support. Palliat. Care11(2), 88–92 (2017).